Viral Inactivation Global Market Trend, Research Approach, Data Analysis 2017 and Forecast 2023
ReportsWeb.com published “Viral Inactivation Global Market” from its database. This report Strategic recommendations in key business segments based on the market estimations. This report Supply chain trends mapping the latest technological advancements.
(EMAILWIRE.COM, November 03, 2017 ) According to Publisher, the Global Viral Inactivation Market is accounted for $1.99 billion in 2016 and expected to grow at a CAGR of 14.9% to reach $5.29 billion by 2023. Factors such as rapid growth in pharmaceutical and biotechnology industries, strong R&D investments in the life sciences industry, high incidence of chronic diseases and increasing number of new drug launches are driving the market growth. However, the high cost of biologics and biosimilars products, development of expensive equipment for viral inactivation are inhibiting the marketspace.
Request Sample Copy at http://www.reportsweb.com/inquiry&RW00011197173/sample
Based on method, the Alkylating agent method segment is considered as the robust & efficient method for inactivation of variety of enveloped viruses. Alkylating agents are monofunctional or bifunctional. Two mechanisms exist for viral inactivation with alkylating agents. One mechanism involves the modification of proteins, which would cause inhibition of viral cell entry or the release of the genome. Also, Formalin and β-propiolactone (β-PL) are used for inactivation of viruses via chemical reaction along with viral capsid proteins and nucleic acids. Alkylating agents permeate the protein capsid of viruses and chemically inactivate the nucleic acid. The alkylating agent N-acetyl-aziridine is a virus inactivate that has been used in vaccine preparation.
Based on product, the usage of kits and reagents has increased tremendously. Two nucleic acid extraction buffers available commercially are used to inactivate the viral stocks. These are TRIzol® LS reagent (Invitrogen Corp.) and AVL Buffer from the Qiamp viral RNA mini kit (Qiagen). North America has dominated the market during the forecast period due to adoption of many methods by blood testing centre. According to the FDA, 41 novel drugs were approved. Increase in funding has also resulted in growth in number of FDA approvals over the recent years.
Some of the key players in Global Viral Inactivation market are Macopharma SA, Charles River Laboratories International, Inc., Clean Cells Inc., Danaher Corporation, Merck KGAA, Parker Hannifin Corporation, Rad Source Technologies, Inc., SGS SA, Sartorius AG, Texcell, Inc., Viral Inactivated Plasma Systems SA, Wuxi Pharmatech (Cayman) Inc., Shandong Weigao Group Medical Polymer Company Limited, Cerus Corporation, Terumo BCT, Inc, BioReliance, Thermo Fisher Scientific Inc. and Macopharma SA.
Applications Covered:
-Stem cell products
-Cellular & Gene therapy products
-Blood & Blood tissue products
-Vaccines & Therapeutics
-Tissues & Tissue products
Products Covered:
-Viral inactivation accessories
-Systems and Services
-Kits & Reagents
Methods Covered:
-pH Concentration method
-Alkylating agent method
-Solvent detergent method
-Pasteurization
-Radiation method
-Other Methods
End Users Covered:
-Blood banks and Hospitals
-Academic research institutes
-Pharmaceutical and Biotechnology companies
-Contract Research Organizations
-Other End Users
Inquire before Buying at http://www.reportsweb.com/inquiry&RW00011197173/buying
Regions Covered:
-North America
US
Canada
Mexico
-Europe
Germany
UK
Italy
France
Spain
Rest of Europe
-Asia Pacific
Japan
China
India
Australia
New Zealand
South Korea
Rest of Asia Pacific
-South America
Argentina
Brazil
Chile
Rest of South America
-Middle East & Africa
Saudi Arabia
UAE
Qatar
South Africa
Rest of Middle East & Africa
Company Profiling
11.1 Macopharma SA
11.2 Charles River Laboratories International, Inc.
11.3 Clean Cells Inc.
11.4 Danaher Corporation
11.5 Merck KGAA
11.6 Parker Hannifin Corporation
11.7 Rad Source Technologies, Inc.
11.8 SGS SA
11.9 Sartorius AG
11.10 Texcell, Inc.
11.11 Viral Inactivated Plasma Systems SA
11.12 Wuxi Pharmatech (Cayman) Inc.
11.13 Shandong Weigao Group Medical Polymer Company Limited
11.14 Cerus Corporation
11.15 Terumo BCT, Inc.
11.16 BioReliance
11.17 Thermo Fisher Scientific Inc.
11.18 Macopharma SA
For more information about this report: http://www.reportsweb.com/viral-inactivation-global-market-outlook-2017-2023
Request Sample Copy at http://www.reportsweb.com/inquiry&RW00011197173/sample
Based on method, the Alkylating agent method segment is considered as the robust & efficient method for inactivation of variety of enveloped viruses. Alkylating agents are monofunctional or bifunctional. Two mechanisms exist for viral inactivation with alkylating agents. One mechanism involves the modification of proteins, which would cause inhibition of viral cell entry or the release of the genome. Also, Formalin and β-propiolactone (β-PL) are used for inactivation of viruses via chemical reaction along with viral capsid proteins and nucleic acids. Alkylating agents permeate the protein capsid of viruses and chemically inactivate the nucleic acid. The alkylating agent N-acetyl-aziridine is a virus inactivate that has been used in vaccine preparation.
Based on product, the usage of kits and reagents has increased tremendously. Two nucleic acid extraction buffers available commercially are used to inactivate the viral stocks. These are TRIzol® LS reagent (Invitrogen Corp.) and AVL Buffer from the Qiamp viral RNA mini kit (Qiagen). North America has dominated the market during the forecast period due to adoption of many methods by blood testing centre. According to the FDA, 41 novel drugs were approved. Increase in funding has also resulted in growth in number of FDA approvals over the recent years.
Some of the key players in Global Viral Inactivation market are Macopharma SA, Charles River Laboratories International, Inc., Clean Cells Inc., Danaher Corporation, Merck KGAA, Parker Hannifin Corporation, Rad Source Technologies, Inc., SGS SA, Sartorius AG, Texcell, Inc., Viral Inactivated Plasma Systems SA, Wuxi Pharmatech (Cayman) Inc., Shandong Weigao Group Medical Polymer Company Limited, Cerus Corporation, Terumo BCT, Inc, BioReliance, Thermo Fisher Scientific Inc. and Macopharma SA.
Applications Covered:
-Stem cell products
-Cellular & Gene therapy products
-Blood & Blood tissue products
-Vaccines & Therapeutics
-Tissues & Tissue products
Products Covered:
-Viral inactivation accessories
-Systems and Services
-Kits & Reagents
Methods Covered:
-pH Concentration method
-Alkylating agent method
-Solvent detergent method
-Pasteurization
-Radiation method
-Other Methods
End Users Covered:
-Blood banks and Hospitals
-Academic research institutes
-Pharmaceutical and Biotechnology companies
-Contract Research Organizations
-Other End Users
Inquire before Buying at http://www.reportsweb.com/inquiry&RW00011197173/buying
Regions Covered:
-North America
US
Canada
Mexico
-Europe
Germany
UK
Italy
France
Spain
Rest of Europe
-Asia Pacific
Japan
China
India
Australia
New Zealand
South Korea
Rest of Asia Pacific
-South America
Argentina
Brazil
Chile
Rest of South America
-Middle East & Africa
Saudi Arabia
UAE
Qatar
South Africa
Rest of Middle East & Africa
Company Profiling
11.1 Macopharma SA
11.2 Charles River Laboratories International, Inc.
11.3 Clean Cells Inc.
11.4 Danaher Corporation
11.5 Merck KGAA
11.6 Parker Hannifin Corporation
11.7 Rad Source Technologies, Inc.
11.8 SGS SA
11.9 Sartorius AG
11.10 Texcell, Inc.
11.11 Viral Inactivated Plasma Systems SA
11.12 Wuxi Pharmatech (Cayman) Inc.
11.13 Shandong Weigao Group Medical Polymer Company Limited
11.14 Cerus Corporation
11.15 Terumo BCT, Inc.
11.16 BioReliance
11.17 Thermo Fisher Scientific Inc.
11.18 Macopharma SA
For more information about this report: http://www.reportsweb.com/viral-inactivation-global-market-outlook-2017-2023
Contact Information:
ReportsWeb.com
Rajat Sahni
Tel: +1-646-491-9876
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results
ReportsWeb.com
Rajat Sahni
Tel: +1-646-491-9876
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results